JAGUAR HEALTH, INC. Noncontrolling Interest, Increase from Sale of Parent Equity Interest
JAGUAR HEALTH, INC. (JAGX) reported Noncontrolling Interest, Increase from Sale of Parent Equity Interest of $160.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest · last filed 2026-04-07
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for the quarter ending 2025-09-30 was $160.00K.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for the quarter ending 2024-06-30 was $148.00K, a 83.39% decline year-over-year.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for the quarter ending 2023-12-31 was -$120.00K.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for the quarter ending 2023-09-30 was $755.00K.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for fiscal 2024 was $727.00K, a 14.49% increase from fiscal 2023.
- JAGUAR HEALTH, INC. noncontrolling interest, increase from sale of parent equity interest for fiscal 2023 was $635.00K.
| Period end | Noncontrolling Interest, Increase from Sale of Parent Equity Interest 3 month | Noncontrolling Interest, Increase from Sale of Parent Equity Interest 6 month | Noncontrolling Interest, Increase from Sale of Parent Equity Interest 9 month | Noncontrolling Interest, Increase from Sale of Parent Equity Interest 12 month |
|---|---|---|---|---|
| 2025-09-30 | $160.00K 10-Q · filed 2025-11-14 | $477.00K 10-Q · filed 2025-11-14 | ||
| 2024-12-31 | $727.00K 10-K · filed 2026-04-07 | |||
| 2024-06-30 | $148.00K 10-Q · filed 2025-08-14 | $264.00K 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | -$120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $635.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.53M derived: sum of 3 quarters · filed 2025-03-31 | $635.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $755.00K 10-Q · filed 2023-11-14 | $1.65M derived: sum of 2 quarters · filed 2023-11-14 | $755.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $891.00K 10-Q · filed 2023-08-14 | $891.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.00M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |